ADMA Biologics (NASDAQ:ADMA) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of ADMA Biologics (NASDAQ:ADMA) in a report issued on Friday, Benzinga reports. They currently have a $20.00 price target on the biotechnology company’s stock.

Other analysts also recently issued research reports about the company. Mizuho boosted their price objective on ADMA Biologics from $12.00 to $14.00 and gave the stock a buy rating in a research note on Thursday, June 20th. HC Wainwright boosted their price target on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a buy rating in a research report on Monday, August 12th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of Buy and an average price target of $15.50.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $19.98 on Friday. The stock has a market cap of $4.63 billion, a P/E ratio of -999.00 and a beta of 0.61. The firm’s 50-day simple moving average is $15.77 and its 200 day simple moving average is $11.00. ADMA Biologics has a fifty-two week low of $3.06 and a fifty-two week high of $20.16. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The company had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. During the same period in the prior year, the business posted ($0.02) EPS. The business’s revenue for the quarter was up 78.4% compared to the same quarter last year. Equities analysts expect that ADMA Biologics will post 0.49 EPS for the current year.

Insider Transactions at ADMA Biologics

In related news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the transaction, the director now owns 241,441 shares in the company, valued at $4,408,712.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The disclosure for this sale can be found here. Insiders have sold 466,900 shares of company stock valued at $8,224,121 over the last three months. Company insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

Several institutional investors and hedge funds have recently bought and sold shares of the business. D. E. Shaw & Co. Inc. grew its position in ADMA Biologics by 26.8% during the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after purchasing an additional 1,442,799 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of ADMA Biologics by 1.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,382,174 shares of the biotechnology company’s stock valued at $37,813,000 after acquiring an additional 35,707 shares in the last quarter. Driehaus Capital Management LLC increased its stake in shares of ADMA Biologics by 17.3% in the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock worth $33,860,000 after acquiring an additional 447,743 shares during the last quarter. Mesirow Institutional Investment Management Inc. purchased a new stake in shares of ADMA Biologics during the first quarter worth $17,221,000. Finally, Renaissance Technologies LLC boosted its position in ADMA Biologics by 28.7% during the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock valued at $28,868,000 after purchasing an additional 575,100 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.